Replies to post #421909 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

No, traders have no impact on the FDA typically, but negative spin without positive affirmation that these unusual circumstances are approvable can take on a political or falsely political air. The FDA is being very careful and slow rolling out it’s reforms and are still sitting on some because they want to ensure that the influencers and opinion leaders are in agreement, not RE this trial but about the reforms. The company still needs to ensure that as an early test case for those reforms, they do not put the FDA in a politically awkward spot and a journal article ensures that the noise that traders will generate or rivals, even if it comes from a critic with some credentials, which is unlikely, is marginalized.

[skitahoe]

Marty,

I'd certainly agree that LP doesn't care about the day to day share price, but I believe she very much cares about the long term share price and/or a partnership or buyout that achieves the maximum price for all. I don't know if she's our largest share holders, but she's certainly among the biggest shareholders, especially after her options and warrants are converted to shares.

Many here like to make comparisons with CVM, I can't imagine two more different companies. CVM's CEO will issue a PR for even the most minor of issues, while LP says nearly nothing unless SEC rules say that she must. CVM has had multiple trial failures with the same drug, they just keep finding new targets to try it on, I believe it's been many years since they made any improvement on the drug itself. NWBO has had one long running pivotal trial which has been modified while underway, because of what was learned in the trial, and they've gotten the concurrence of the regulators to make the changes.

None of us like the lower share price, if we're not looking to buy cheap shares, but if you're not planning to sell, the only real concern is what it will do long term, and that's what I believe is what LP cares about.

Gary